125 related articles for article (PubMed ID: 7744111)
1. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1995; 16(1):12-7. PubMed ID: 7744111
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
[TBL] [Abstract][Full Text] [Related]
6. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Cancer; 1989 Apr; 63(8):1509-13. PubMed ID: 2924259
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
Piver MS; Recio FO; Baker TR; Driscoll D
Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. A reassessment based on mature data.
Ben-Baruch G; Menczer J; Feldman B; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1994; 15(4):272-6. PubMed ID: 7957334
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
[TBL] [Abstract][Full Text] [Related]
12. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
Fanning J; Hilgers RD; Hutson E
Am J Clin Oncol; 1994 Aug; 17(4):335-7. PubMed ID: 8048396
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
16. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
17. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
[TBL] [Abstract][Full Text] [Related]
18. First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
Athanassiou AE; Bafaloukos D; Pectasides D; Dimitriadis M; Varthalitis I; Barbounis V
Br J Cancer; 1989 Nov; 60(5):755-8. PubMed ID: 2803952
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus VP 16-213 in advanced ovarian carcinoma.
Harnett PR; Bell DR; Hillcoat BL; Woods RL; Levi JA; Rome RM; Campbell JC; Tattersall MH
Gynecol Oncol; 1988 Jun; 30(2):159-62. PubMed ID: 3371739
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]